Background. Rituximab is becoming increasingly utilized in renal transplant recipients; however, its association with infections remains unclear. Methods. We reviewed the incidence of viral and fungal infections in kidney transplant recipients treated with ( = 55) or without ( = 386) rituximab (RTX) in addition to standard immunosuppression. Results. Infections occurred in 134 (30%) patients, with a greater proportion in RTX versus no RTX patients (47% versus 28%; = 0.005). Viral infections occurred in 44% and 27% of RTX and no RTX patients, respectively ( = 0.012). This was largely driven by the frequency of BK viremia and noncytomegalovirus/non-BK viruses in RTX patients (27% versus 13% ( = 0.011) and 15% versus 2% ( < 0.001), resp.). Fungal infections also occurred more often in RTX patients (11% versus 3 %; = 0.009). Multivariate analysis revealed deceased donor recipient (odds ratio = 2.5; < 0.001) and rituximab exposure (odds ratio = 2.2; = 0.016) as independent risk factors for infection. Older patients, deceased donor recipients, those on dialysis longer, and those with delayed graft function tended to be at a greater risk for infections following rituximab. Conclusions. Rituximab is associated with an increased incidence of viral and fungal infections in kidney transplantation. Additional preventative measures and/or monitoring infectious complications may be warranted in those receiving rituximab.